Cancer Stem Cell News Volume 4.27 | Jul 22 2015

CD34⁺ Liver Cancer Stem Cells Were Formed by Fusion of Hepatobiliary Stem/Progenitor Cells with Hematopoietic Precursor-Derived Myeloid Intermediates
Researchers found that CD34⁺ lung cancer stem cells co-expressed liver stem cell and myelomonocytic cell markers, showing a mixed phenotype, a combination of hepatobiliary stem/progenitor cells and myelomonocytic cells. [Stem Cells Dev] Abstract

miR-491 Attenuates Cancer Stem Cells-Like Properties of Hepatocellular Carcinoma by Inhibition of GIT-1/NF-κB-Mediated EMT.
Scientists showed that microRNA (miR)-491 had a negative relationship with cancer stem cell (CSC)-like properties both in cell lines and tissue samples of hepatocellular carcinoma (HCC). In HCC cell lines, nuclear factor kappa B (NF-κB)/snail pathway was involved in the epithelial to mesenchymal transition and the maintenance of CSCs-like properties. [Tumor Biol] Abstract

Prolonged and Repetitive Exposure to Porphyromonas gingivalis Increases Aggressiveness of Oral Cancer Cells by Promoting Acquisition of Cancer Stem Cell Properties
Repeated infection of oral cancer cells by P. gingivalis resulted in morphological changes of host cancer cells into an elongated shape, along with the decreased expression of epithelial cell markers, suggesting acquisition of an epithelial-to-mesenchymal transition phenotype. [Tumor Biol] Abstract

Treatment Analysis in a Cancer Stem Cell Context Using a Tumor Growth Model Based on Cellular Automata
A cellular automata model based on the presence of hallmarks in the cells, which includes a simulation of the behavior of cancer stem cells and their implications for the resultant growth behavior of the multicellular system, was employed. This modeling of cancer growth, in the avascular phase, was employed to analyze the effect of cancer treatments in a cancer stem cell context. [PLoS One] Full Article

Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells
Researchers studied the role of BORIS (brother of regulator of imprinted sites) in epithelial tumor cells. Using BORIS-molecular beacon that was already validated, they were able to show the presence of BORIS mRNA in cancer stem cell-enriched populations (side population and spheres) of cervical, colon and breast tumor cells. [PLoS One] Full Article

A Pivotal Role of Krüppel-Like Factor 5 in Regulation of Cancer Stem-Like Cells in Hepatocellular Carcinoma
Krüppel-like factor 5 (KLF5) overexpression enriched the CD44^High/CD133^High subpopulation and, consistent with the up-regulation of CD44^High/CD133^High, KLF5 overexpressing cells were more resistant to anti-cancer drugs and displayed enhanced colony-formation capacity. [Cancer Biol Ther] Abstract

Regulation of Stem Cells-Related Signaling Pathways in Response to Doxorubicin Treatment in Hs578T Triple-Negative Breast Cancer Cells
The authors investigated the cellular and molecular signaling of two claudin-low triple-negative breast cancer cells to doxorubicin and docetaxel treatment. While the treatment reduced the proliferation, aggregation and mammosphere forming ability of stem-like cells derived from Hs578T cell line, stem-like cells derived from MDA-MB-231 cells were not significantly affected. [Mol Cell Biochem] Abstract

Existing Drugs and Their Application in Drug Discovery Targeting Cancer Stem Cells
The authors introduce the latest examples of attempted drug repositioning targeting cancer stem cells and discuss potential use of the repositioned drugs for cancer therapy. [Arch Pharm Res] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

From our sponsor: Culturing hematopoietic stem and progenitor cells? Download the technical bulletin.

CANbridge Acquires License for Apogenix’s APG101 Onco-Immunotherapy in Glioblastoma for China
CANbridge Life Sciences has entered into an exclusive license agreement with Apogenix to develop, manufacture and commercialize Apogenix’s lead product, APG101, in glioblastoma multiforme in China, Macao, and Hong Kong, with options for other indications. [CANbridge Life Sciences Ltd.] Press Release

Damon Runyon Foundation Grants Prestigious Fellowship Awards to 16 Top Young Scientists
The Damon Runyon Cancer Research Foundation named 16 new Damon Runyon Fellows at its spring Fellowship Award Committee review. The recipients of this prestigious, four-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country. [Damon Runyon Foundation] Press Release

Patient’s Gift Creates Endowed Professorship for Leukemia Research at UChicago
Anjuli Nayak, a renowned allergist and immunologist from Bloomington who received cancer treatment at the University of Chicago Medicine, is endowing a $3.5 million professorship at the medical center for leukemia research. [University of Chicago Medicine] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Postdoctoral Cancer Research – Molecular Targets for Tumor Therapy (University of Würzburg)

NEW Higher Scientific Officer – Cancer Proteomics (Institute of Cancer Research)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Positions- Cancer Research (Rutgers University)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center)

Postdoctoral Researcher – Tumor Immunology and Cancer Immunotherapy (University of California, Los Angeles)

Professor – Cancer Stem Cells (Dalian Medical University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.